ERT Cardiac Safety Solution Surpasses 10,000th Clinical Study

PHILADELPHIA – November 20, 2019 – ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials, today announced it has reached a significant milestone: Global biopharmaceutical companies have relied on ERT’s centralized cardiac safety solution to assess the safety of their new medical compounds in more than 10,000 clinical studies across all phases of clinical development.

“It’s truly an honor to support our customers and to deliver the highly precise cardiac safety data they need to ensure patient safety,” said James Corrigan, President and CEO, ERT. “We’re privileged to have earned the trust of so many world-leading researchers who recognize the value of centralization and have leveraged ERT’s scientific, technological and operational expertise to uncover and address potential patient safety issues during clinical development.”

An industry leader, ERT has a rich history of innovation in cardiac safety assessment, including pioneering research that led to revised ICH E14 regulatory guidance enabling clinical trial sponsors to better prioritize their pipelines by characterizing QT earlier in clinical development. And, its proven, centralized approach reduces improper inclusion and exclusion decisions, ensuring that only the correct patients participate in clinical trials, further ensuring their safety while accelerating study timelines.

“Reaching the 10,000^th study milestone is a testament to the dedication of our entire cardiac safety team,” said Ellen Street, Executive Vice President, Cardiac Safety, ERT. “Their passion for helping our customers bring new medical treatments to patients in need has enabled us to continue delivering cardiac safety solutions that are not only technologically advanced, but most importantly, ensure patient safety.”

For more information on ERT’s suite of cardiac solutions, visit ert.com/cardiac-safety.